Trial Profile

A Phase II Trial of TXA127 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Angiotensin-1-7 (Primary)
Indications Epidermolysis bullosa; Epidermolysis bullosa dystrophica
Focus Therapeutic Use
Sponsors Constant Therapeutics

Most Recent Events

28 Feb 2019 According to a LifeArc media release, this trial will be carried out by Constant Therapeutics which, with the additional funding, has been able to add this recessive dystrophic epidermolysis bullosa (RDEB) study to its clinical development plan for TXA127.This trial is expected to begin in 2020.
22 Jan 2019 According to a Constant Therapeutics media release, the company announced that they are changing their name from Constant Pharmaceuticals, LLC, to Constant Therapeutics, LLC.
09 Dec 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com